Miscellaneous Malignancies | Norton Healthcare

Indication: Miscellaneous Malignancies

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

Sub-indication: Miscellaneous Malignancies

Drug Study

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: Seattle Genetics, Inc

Learn more at ClinicalTrials.gov

Email for more information: CancerResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.